Abstract

BACKGROUND: To date there has been no large-scale, real-world study of health-related quality of life outcomes for patients using Tumor Treating Fields (TTFields) therapy for glioblastoma (GBM) treatment. METHODS: A survey was mailed to 2,815 patients actively using TTFields for treatment of GBM in the US (n=2,182) and Europe (n=633). The survey included patient-reported demographic and clinical information as well as EuroQol’s EQ-5D-5L and Visual Analogue Scale (EQ-VAS) overall health score. RESULTS: 1,106 applicable patients responded to the survey (782 US, 324 Europe) with a mean age of 58.6 years (SD=12.3). Average time since diagnosis and time using TTFields were 21.5 months (SD=25.1) and 13.5 months (SD=13.2) respectively. Over 61% of patients had been diagnosed at least 1 year prior, 28.4% at least 2 years prior and 45 patients (4.2%) had been diagnosed at least 5 years prior. Progressed disease was reported in 307 patients while 690 reported non-progressed disease. Regression analyses showed that GBM disease progression and older age had predictable negative associations (p<.001) with most EQ-5D-5L dimensions and the EQ-VAS. However, longer time since diagnosis was associated with improved self-care (p<.05), usual activity (p<.01), and EQ-VAS (p<.05) overall and in patients with progressed disease (p<.01, .05, .01 respectively). Additionally, longer time using TTFields was associated with improved mobility (p<0.05), self-care (p<.001), usual activity (p<0.01), and EQ-VAS (p<0.01) overall, with improved EQ-VAS in progression-free patients (p<.05), and with improved mobility (p<.05), self-care (p<.01), usual activity (p<.05), and EQ-VAS (p<.05) in patients with progressed disease. CONCLUSION: This is the largest real-world study of patient-reported quality of life in GBM and TTFields treatment to date. It shows unsurprising negative associations between quality of life and disease progression and older age as well as more novel, positive associations between quality of life and longer time since diagnosis and time using TTFields therapy.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.